Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
THIS PRESS RELEASE AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR PUBLIC RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED...
-
Kiadis Pharma files first...
-
EBMT Abstract #A-1137-0005-00784 Amsterdam, The Netherlands, March 10, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage...
-
Amsterdam, The Netherlands, March 4, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...
-
Amsterdam, The Netherlands, February 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, and The Ohio State...
-
Amsterdam, The Netherlands, December 11, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...
-
Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual Healthcare Conference Amsterdam, The Netherlands, November 25, 2019 – Kiadis Pharma...
-
Kiadis will focus all future investments on developing off-the-shelf and haplo donor NK-cell therapies for the treatment of solid and liquid tumorsDiscontinues development of ATIR101, stopping...
-
ASH Abstract # ATIR101: 592, 4464; NK-cell Therapy (K-NK002) 1955 Phase II data analysis of ATIR101 as an adjunctive treatment following T-cell depleted haploidentical hematopoietic stem...
-
Amsterdam, The Netherlands, November 5, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces...